5-Amino-1MQ
A small molecule that targets fat metabolism at the enzymatic level. 5-Amino-1MQ inhibits NNMT — an enzyme that gets overexpressed in fat cells and contributes to metabolic dysfunction and obesity.
5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), an enzyme overactive in fat tissue that depletes NAD+ and promotes fat storage. By blocking NNMT, this compound may increase cellular NAD+ levels, enhance fat oxidation, and reduce adipocyte (fat cell) size. All evidence is from cell culture and animal models.
Who's interested: Biohackers interested in metabolic optimisation and fat loss. This is a very early-stage compound with no human safety data.
Dive deeper into the researchPotential side effects
- Unknown — no human trials exist
- Possible GI discomfort (anecdotal)
- Theoretical NAD+ pathway disruption at incorrect doses
What does 5-Amino-1MQ do?
Fat cells that become metabolically dysfunctional tend to overexpress an enzyme called NNMT (nicotinamide N-methyltransferase). This enzyme burns through your NAD+ supply and promotes a metabolic state that favors fat storage over fat burning.
5-Amino-1MQ blocks NNMT. In cell and animal studies, this leads to higher intracellular NAD+ levels, smaller and more metabolically active fat cells, and reduced overall adiposity — without affecting food intake.
Who uses it?
- Fat loss seekers — people looking for metabolic support beyond diet and exercise
- NAD+ optimisers — those interested in raising NAD+ through a different pathway than NMN/NR
- Metabolic researchers — studying NNMT as a drug target for obesity
What to know before trying
5-Amino-1MQ has zero human clinical trials. Cell culture and animal data look promising, but this compound has not been tested for safety or efficacy in people. Oral bioavailability and pharmacokinetics in humans are unknown.
- Oral convenience — unlike most peptides, this is taken as a capsule
- Not technically a peptide — it's a small molecule NNMT inhibitor, but discussed in peptide communities
- Complements NMN/NR — theoretically, blocking NNMT (which consumes NAD+) while supplementing NAD+ precursors could be synergistic
- Quality concerns — purity verification is essential; limited vendors carry it
Tracking a peptide protocol?
eterni connects your labs, supplements, and retests — so you can see whether your protocol is actually working.
Get early accessFrequently Asked Questions
What is 5-Amino-1MQ?
5-Amino-1MQ is a small molecule that inhibits NNMT (nicotinamide N-methyltransferase), an enzyme overexpressed in fat tissue that depletes NAD+ and promotes fat storage. By blocking this enzyme, it may increase NAD+ levels, shrink fat cells, and improve metabolic function. All evidence is from cell and animal studies.
Does 5-Amino-1MQ help with weight loss?
In animal studies, NNMT inhibition reduced fat mass without changing food intake. However, no human trials have confirmed this effect. If it works in humans, it would complement — not replace — diet and exercise.
Is 5-Amino-1MQ the same as NMN?
No. NMN provides raw material (NAD+ precursor) for your body to make more NAD+. 5-Amino-1MQ blocks an enzyme that wastes NAD+. They're complementary approaches to the same goal — higher NAD+ levels — but work through different mechanisms.
Is 5-Amino-1MQ safe?
Unknown. No human safety data exists. The compound is well-tolerated in cell culture and animal studies, but human pharmacokinetics, drug interactions, and long-term effects are completely unstudied.
How it works
- NNMT inhibition — blocks the enzyme that methylates (and wastes) nicotinamide, preserving the NAD+ precursor pool
- NAD+ elevation — indirectly raises intracellular NAD+ by preventing its precursor from being consumed
- Fat cell remodeling — reduces adipocyte size and shifts metabolism toward fat oxidation
- SAM conservation — NNMT also consumes S-adenosylmethionine (SAM); blocking it preserves methylation capacity
Preclinical evidence
- NNMT inhibition reduced fat mass by ~30% in diet-induced obese mice without affecting lean mass or food intake
- Fat cells treated with NNMT inhibitors showed smaller size, increased lipolysis, and improved insulin sensitivity
- NNMT is overexpressed 2–3x in obese human adipose tissue vs lean tissue
Side effects & safety
No human safety data. Theoretical considerations:
- Methylation disruption — NNMT plays a role in methylation metabolism; long-term inhibition effects unknown
- GI effects — anecdotal reports of mild stomach discomfort
- Drug interactions — unstudied but plausible given the metabolic pathway involvement
- Liver metabolism — oral compounds require hepatic processing; no toxicology data
Who should avoid it: People on medications affecting methylation (methotrexate, etc.), those with liver conditions, pregnant or breastfeeding women, and anyone uncomfortable with zero human data.
Know what's working. Know what's not.
eterni connects your lab results, supplements, and retests — so you can see the trajectory, not just a snapshot.
Join the waitlist